25 XP   0   0   10

Celldex Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Celldex together

PenkeI guess you are interested in Celldex Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Celldex Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Celldex Therapeutics Inc

I send you an email if I find something interesting about Celldex Therapeutics Inc.

Quick analysis of Celldex (30 sec.)










What can you expect buying and holding a share of Celldex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.53
Expected worth in 1 year
$8.10
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
$1.57
Return On Investment
4.3%

For what price can you sell your share?

Current Price per Share
$36.26
Expected price per share
$33.55 - $53.18
How sure are you?
50%

1. Valuation of Celldex (5 min.)




Live pricePrice per Share (EOD)

$36.26

Intrinsic Value Per Share

$-30.23 - $-15.46

Total Value Per Share

$-23.70 - $-8.93

2. Growth of Celldex (5 min.)




Is Celldex growing?

Current yearPrevious yearGrowGrow %
How rich?$429.1m$358.7m-$44.6m-14.2%

How much money is Celldex making?

Current yearPrevious yearGrowGrow %
Making money-$33.6m-$30.6m-$2.9m-8.7%
Net Profit Margin-4,317.4%-13,061.2%--

How much money comes from the company's main activities?

3. Financial Health of Celldex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#134 / 1010

Most Revenue
#455 / 1010

Most Profit
#818 / 1010

Most Efficient
#894 / 1010

What can you expect buying and holding a share of Celldex? (5 min.)

Welcome investor! Celldex's management wants to use your money to grow the business. In return you get a share of Celldex.

What can you expect buying and holding a share of Celldex?

First you should know what it really means to hold a share of Celldex. And how you can make/lose money.

Speculation

The Price per Share of Celldex is $36.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Celldex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Celldex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.53. Based on the TTM, the Book Value Change Per Share is $0.39 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Celldex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.66-1.8%-0.54-1.5%-0.43-1.2%-0.33-0.9%-0.40-1.1%
Usd Book Value Change Per Share2.787.7%0.391.1%-0.35-1.0%0.230.6%0.040.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.787.7%0.391.1%-0.35-1.0%0.230.6%0.040.1%
Usd Price Per Share39.66-34.27-33.43-23.82-16.30-
Price to Earnings Ratio-15.04--16.31--20.36--17.49--11.37-
Price-to-Total Gains Ratio14.28--58.39--101.15--67.21--33.39-
Price to Book Ratio6.07-7.31-6.20-5.46-3.78-
Price-to-Total Gains Ratio14.28--58.39--101.15--67.21--33.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share36.26
Number of shares27
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.390.23
Usd Total Gains Per Share0.390.23
Gains per Quarter (27 shares)10.586.27
Gains per Year (27 shares)42.3225.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10423202515
20857405040
3012711607565
40169158010090
502122000125115
602542420150140
702962840176165
803393260201190
903813680226215
1004234100251240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%2.0133.00.01.5%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%30.0104.01.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0135.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%30.0104.01.022.2%

Fundamentals of Celldex

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 04:17:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Celldex Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Celldex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Celldex to the Biotechnology industry mean.
  • A Net Profit Margin of -1,048.3% means that $-10.48 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Celldex Therapeutics Inc:

  • The MRQ is -1,048.3%. The company is making a huge loss. -2
  • The TTM is -4,317.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,048.3%TTM-4,317.4%+3,269.1%
TTM-4,317.4%YOY-13,061.2%+8,743.8%
TTM-4,317.4%5Y-5,285.0%+967.6%
5Y-5,285.0%10Y-3,789.7%-1,495.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,048.3%-207.2%-841.1%
TTM-4,317.4%-216.8%-4,100.6%
YOY-13,061.2%-282.3%-12,778.9%
5Y-5,285.0%-436.8%-4,848.2%
10Y-3,789.7%-597.3%-3,192.4%
1.1.2. Return on Assets

Shows how efficient Celldex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Celldex to the Biotechnology industry mean.
  • -9.3% Return on Assets means that Celldex generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Celldex Therapeutics Inc:

  • The MRQ is -9.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.3%TTM-10.0%+0.7%
TTM-10.0%YOY-7.9%-2.1%
TTM-10.0%5Y-8.1%-1.9%
5Y-8.1%10Y-9.8%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.3%-13.3%+4.0%
TTM-10.0%-12.8%+2.8%
YOY-7.9%-11.6%+3.7%
5Y-8.1%-13.8%+5.7%
10Y-9.8%-15.6%+5.8%
1.1.3. Return on Equity

Shows how efficient Celldex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Celldex to the Biotechnology industry mean.
  • -10.1% Return on Equity means Celldex generated $-0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Celldex Therapeutics Inc:

  • The MRQ is -10.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.1%TTM-11.0%+0.9%
TTM-11.0%YOY-8.6%-2.4%
TTM-11.0%5Y-9.4%-1.6%
5Y-9.4%10Y-12.0%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.1%-16.9%+6.8%
TTM-11.0%-16.1%+5.1%
YOY-8.6%-14.9%+6.3%
5Y-9.4%-19.3%+9.9%
10Y-12.0%-20.1%+8.1%

1.2. Operating Efficiency of Celldex Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Celldex is operating .

  • Measures how much profit Celldex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Celldex to the Biotechnology industry mean.
  • An Operating Margin of -850.3% means the company generated $-8.50  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Celldex Therapeutics Inc:

  • The MRQ is -850.3%. The company is operating very inefficient. -2
  • The TTM is -5,200.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-850.3%TTM-5,200.9%+4,350.6%
TTM-5,200.9%YOY-11,057.2%+5,856.2%
TTM-5,200.9%5Y-5,112.1%-88.8%
5Y-5,112.1%10Y-3,698.9%-1,413.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-850.3%-298.0%-552.3%
TTM-5,200.9%-238.5%-4,962.4%
YOY-11,057.2%-288.4%-10,768.8%
5Y-5,112.1%-486.2%-4,625.9%
10Y-3,698.9%-628.4%-3,070.5%
1.2.2. Operating Ratio

Measures how efficient Celldex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.50 means that the operating costs are $9.50 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Celldex Therapeutics Inc:

  • The MRQ is 9.503. The company is inefficient in keeping operating costs low. -1
  • The TTM is 50.311. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.503TTM50.311-40.808
TTM50.311YOY100.691-50.380
TTM50.3115Y54.021-3.710
5Y54.02110Y50.034+3.987
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5033.235+6.268
TTM50.3113.310+47.001
YOY100.6913.838+96.853
5Y54.0215.679+48.342
10Y50.0347.823+42.211

1.3. Liquidity of Celldex Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Celldex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.87 means the company has $13.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Celldex Therapeutics Inc:

  • The MRQ is 13.870. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.665. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.870TTM14.665-0.795
TTM14.665YOY19.184-4.519
TTM14.6655Y14.717-0.052
5Y14.71710Y11.999+2.718
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.8703.863+10.007
TTM14.6654.169+10.496
YOY19.1845.337+13.847
5Y14.7176.122+8.595
10Y11.9996.434+5.565
1.3.2. Quick Ratio

Measures if Celldex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Celldex to the Biotechnology industry mean.
  • A Quick Ratio of 26.12 means the company can pay off $26.12 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Celldex Therapeutics Inc:

  • The MRQ is 26.124. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 26.476. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ26.124TTM26.476-0.352
TTM26.476YOY35.807-9.331
TTM26.4765Y26.406+0.070
5Y26.40610Y21.179+5.227
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ26.1243.504+22.620
TTM26.4763.991+22.485
YOY35.8075.371+30.436
5Y26.4066.088+20.318
10Y21.1796.395+14.784

1.4. Solvency of Celldex Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Celldex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Celldex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Celldex assets are financed with 7.8% credit (debt) and the remaining percentage (100% - 7.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Celldex Therapeutics Inc:

  • The MRQ is 0.078. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.084. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.078TTM0.084-0.006
TTM0.084YOY0.074+0.011
TTM0.0845Y0.123-0.038
5Y0.12310Y0.157-0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0780.339-0.261
TTM0.0840.337-0.253
YOY0.0740.271-0.197
5Y0.1230.368-0.245
10Y0.1570.388-0.231
1.4.2. Debt to Equity Ratio

Measures if Celldex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Celldex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.5% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Celldex Therapeutics Inc:

  • The MRQ is 0.085. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.093. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.085TTM0.093-0.008
TTM0.093YOY0.080+0.013
TTM0.0935Y0.147-0.055
5Y0.14710Y0.200-0.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0850.392-0.307
TTM0.0930.403-0.310
YOY0.0800.335-0.255
5Y0.1470.427-0.280
10Y0.2000.461-0.261

2. Market Valuation of Celldex Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Celldex generates.

  • Above 15 is considered overpriced but always compare Celldex to the Biotechnology industry mean.
  • A PE ratio of -15.04 means the investor is paying $-15.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Celldex Therapeutics Inc:

  • The EOD is -13.752. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.042. Based on the earnings, the company is expensive. -2
  • The TTM is -16.313. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.752MRQ-15.042+1.290
MRQ-15.042TTM-16.313+1.272
TTM-16.313YOY-20.361+4.048
TTM-16.3135Y-17.493+1.180
5Y-17.49310Y-11.367-6.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.752-2.300-11.452
MRQ-15.042-2.656-12.386
TTM-16.313-2.718-13.595
YOY-20.361-4.145-16.216
5Y-17.493-6.258-11.235
10Y-11.367-6.315-5.052
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Celldex Therapeutics Inc:

  • The EOD is -17.939. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -19.621. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -20.921. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.939MRQ-19.621+1.682
MRQ-19.621TTM-20.921+1.299
TTM-20.921YOY-21.968+1.048
TTM-20.9215Y-22.025+1.105
5Y-22.02510Y-13.900-8.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.939-2.974-14.965
MRQ-19.621-3.306-16.315
TTM-20.921-3.508-17.413
YOY-21.968-5.613-16.355
5Y-22.025-8.378-13.647
10Y-13.900-8.873-5.027
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Celldex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.07 means the investor is paying $6.07 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Celldex Therapeutics Inc:

  • The EOD is 5.551. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.071. Based on the equity, the company is overpriced. -1
  • The TTM is 7.310. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.551MRQ6.071-0.520
MRQ6.071TTM7.310-1.239
TTM7.310YOY6.199+1.111
TTM7.3105Y5.463+1.847
5Y5.46310Y3.780+1.683
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.5511.914+3.637
MRQ6.0712.116+3.955
TTM7.3102.097+5.213
YOY6.1992.881+3.318
5Y5.4633.550+1.913
10Y3.7803.936-0.156
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Celldex Therapeutics Inc.

3.1. Institutions holding Celldex Therapeutics Inc

Institutions are holding 96.798% of the shares of Celldex Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc10.73140.02157050409-38711-0.5461
2023-12-31Wellington Management Company LLP9.8580.04796476561104472819.2334
2023-12-31BlackRock Inc5.59480.0037367569242373813.0303
2023-12-31Eventide Asset Management, LLC5.52522.349936300132030013126.8758
2023-12-31RTW INVESTMENTS, LLC5.27132.1455346320100
2023-12-31Polar Capital Holdings PLC4.77310.7619313587170911529.2207
2023-12-31Vanguard Group Inc4.63680.0026304633142782716.3386
2023-12-31Kynam Capital Management, LP4.575313.20773005904-194096-6.0655
2023-12-31Bellevue Group AG3.67781.4659241629651629627.1735
2023-12-31State Street Corporation3.61850.00462377326844753.6843
2023-12-31Pictet Asset Manangement SA3.38740.0974222544837447820.2314
2023-09-30Redmile Group, LLC2.49012.14211635938-60066-3.5416
2023-09-30Point72 Asset Management, L.P.2.04330.1078134240015760013.3018
2023-12-31Marshall Wace Asset Management Ltd1.94840.0861280084741765137.7928
2023-12-31Geode Capital Management, LLC1.70170.0046111799411756911.7519
2023-12-31Rock Springs Capital Management LP1.47590.946796964646954593.89
2023-12-31Goldman Sachs Group Inc1.33260.0031875518463684112.59
2023-12-31Sofinnova Ventures1.28471.873184400841974998.937
2023-09-30Octagon Capital Advisors LP1.15663.212875989800
2023-12-31Eversept Partners, LLC1.14782.627575410716596428.2183
Total 76.230731.112350082645+7853673+15.7%

3.2. Funds holding Celldex Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Health Care Inv3.37850.1897221965183501060.3052
2023-09-30BB Biotech AG Ord2.8922.141119000001000005.5556
2023-12-31Eventide Gilead N2.76481.8827181644918164490
2023-12-31Eventide Healthcare & Life Sciences I2.75864.3122181236421236413.2728
2024-02-29Polar Capital Biotech S Inc2.66374.7827175000000
2024-02-29Vanguard Total Stock Mkt Idx Inv2.61010.00531714831-6452-0.3748
2024-03-28SPDR® S&P Biotech ETF2.42740.88641594762201201.2778
2024-03-28iShares Russell 2000 ETF2.3160.097515216037350.0483
2023-12-31Vanguard Explorer Inv1.98330.2417130300500
2023-12-31Pictet-Biotech P USD1.71562.83112712419751521.2471
2024-02-29Fidelity Advisor Growth Opps M1.39410.21791590000
2024-02-29Polar Capital Healthcare Opports Inc1.30962.4546860417-142692-14.225
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.22780.03880665211990.1489
2023-12-31Pictet-Global Megatrend Sel I USD1.18550.24677886430946665.9283
2024-02-29Fidelity Select Biotechnology1.02530.658567360000
2024-02-29Fidelity Select Health Care0.91330.3643600000-40000-6.25
2024-01-31Fidelity Small Cap Growth0.8340.3366547915-661-0.1205
2024-01-31Fidelity Series Small Cap Opps0.81920.3664538200-52679-8.9154
2024-02-29Fidelity Advisor Biotechnology I0.78181.388251365200
2024-01-31Fidelity Small Cap Index0.71540.066847003373171.5813
Total 35.71623.505723465022+3257691+13.9%

3.3. Insider Transactions

Insiders are holding 0.347% of the shares of Celldex Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-08-17Sarah CavanaughSELL3131236.73
2022-08-12Samuel Bates MartinSELL1754736.45
2021-12-23Samuel Bates MartinSELL950042
2021-12-08Elizabeth CrowleySELL400040
2021-12-08Sarah CavanaughSELL732340
2021-11-15Samuel Bates MartinSELL950043.57
2021-11-12Diane C YoungSELL460042.94
2021-08-11Freddy A JimenezBUY43046.28
2021-08-10Samuel Bates MartinSELL273845.25

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Celldex Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.7770.392+609%-0.355+113%0.232+1096%0.042+6573%
Book Value Per Share--6.5324.780+37%5.460+20%3.884+68%3.755+74%
Current Ratio--13.87014.665-5%19.184-28%14.717-6%11.999+16%
Debt To Asset Ratio--0.0780.084-7%0.074+6%0.123-36%0.157-50%
Debt To Equity Ratio--0.0850.093-8%0.080+6%0.147-42%0.200-57%
Dividend Per Share----0%-0%-0%-0%
Eps---0.659-0.538-18%-0.427-35%-0.331-50%-0.401-39%
Free Cash Flow Per Share---0.505-0.415-18%-0.402-21%-0.278-45%-0.330-35%
Free Cash Flow To Equity Per Share--2.8030.416+574%-0.386+114%0.241+1064%0.040+6902%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---15.459--------
Intrinsic Value_10Y_min---30.232--------
Intrinsic Value_1Y_max---1.354--------
Intrinsic Value_1Y_min---1.691--------
Intrinsic Value_3Y_max---4.218--------
Intrinsic Value_3Y_min---6.271--------
Intrinsic Value_5Y_max---7.260--------
Intrinsic Value_5Y_min---12.118--------
Market Cap2382234862.000-9%2605610442.0002251658695.750+16%2195979047.500+19%1565041582.050+66%1070810792.794+143%
Net Profit Margin---10.483-43.174+312%-130.612+1146%-52.850+404%-37.897+262%
Operating Margin---8.503-52.009+512%-110.572+1200%-51.121+501%-36.989+335%
Operating Ratio--9.50350.311-81%100.691-91%54.021-82%50.034-81%
Pb Ratio5.551-9%6.0717.310-17%6.199-2%5.463+11%3.780+61%
Pe Ratio-13.752+9%-15.042-16.313+8%-20.361+35%-17.493+16%-11.367-24%
Price Per Share36.260-9%39.66034.273+16%33.425+19%23.822+66%16.299+143%
Price To Free Cash Flow Ratio-17.939+9%-19.621-20.921+7%-21.968+12%-22.025+12%-13.900-29%
Price To Total Gains Ratio13.057-9%14.281-58.394+509%-101.155+808%-67.208+571%-33.392+334%
Quick Ratio--26.12426.476-1%35.807-27%26.406-1%21.179+23%
Return On Assets---0.093-0.100+8%-0.079-15%-0.081-13%-0.098+5%
Return On Equity---0.101-0.110+9%-0.086-15%-0.094-7%-0.120+19%
Total Gains Per Share--2.7770.392+609%-0.355+113%0.232+1096%0.042+6573%
Usd Book Value--429171000.000314041500.000+37%358703500.000+20%255141000.000+68%246689400.000+74%
Usd Book Value Change Per Share--2.7770.392+609%-0.355+113%0.232+1096%0.042+6573%
Usd Book Value Per Share--6.5324.780+37%5.460+20%3.884+68%3.755+74%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.659-0.538-18%-0.427-35%-0.331-50%-0.401-39%
Usd Free Cash Flow---33199000.000-27277250.000-18%-26390000.000-21%-18296450.000-45%-21667800.000-35%
Usd Free Cash Flow Per Share---0.505-0.415-18%-0.402-21%-0.278-45%-0.330-35%
Usd Free Cash Flow To Equity Per Share--2.8030.416+574%-0.386+114%0.241+1064%0.040+6902%
Usd Market Cap2382234862.000-9%2605610442.0002251658695.750+16%2195979047.500+19%1565041582.050+66%1070810792.794+143%
Usd Price Per Share36.260-9%39.66034.273+16%33.425+19%23.822+66%16.299+143%
Usd Profit---43306000.000-33620750.000-22%-30695750.000-29%-21921750.000-49%-26411425.000-39%
Usd Revenue--4131000.0001720750.000+140%589250.000+601%1244100.000+232%1575325.000+162%
Usd Total Gains Per Share--2.7770.392+609%-0.355+113%0.232+1096%0.042+6573%
 EOD+2 -6MRQTTM+22 -11YOY+18 -155Y+19 -1410Y+25 -8

4.2. Fundamental Score

Let's check the fundamental score of Celldex Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.752
Price to Book Ratio (EOD)Between0-15.551
Net Profit Margin (MRQ)Greater than0-10.483
Operating Margin (MRQ)Greater than0-8.503
Quick Ratio (MRQ)Greater than126.124
Current Ratio (MRQ)Greater than113.870
Debt to Asset Ratio (MRQ)Less than10.078
Debt to Equity Ratio (MRQ)Less than10.085
Return on Equity (MRQ)Greater than0.15-0.101
Return on Assets (MRQ)Greater than0.05-0.093
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Celldex Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.057
Ma 20Greater thanMa 5039.383
Ma 50Greater thanMa 10041.968
Ma 100Greater thanMa 20039.625
OpenGreater thanClose36.290
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income Tax Expense  -2,796-4,150-6,9463,487-3,459480-2,97916,36313,384
Total Other Income Expense Net 1,3981,7123,110-4072,7032762,979-11,158-8,179



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets465,627
Total Liabilities36,456
Total Stockholder Equity429,171
 As reported
Total Liabilities 36,456
Total Stockholder Equity+ 429,171
Total Assets = 465,627

Assets

Total Assets465,627
Total Current Assets431,693
Long-term Assets33,934
Total Current Assets
Cash And Cash Equivalents 34,814
Short-term Investments 386,884
Net Receivables 4,528
Other Current Assets 5,467
Total Current Assets  (as reported)431,693
Total Current Assets  (calculated)431,693
+/-0
Long-term Assets
Property Plant Equipment 6,637
Intangible Assets 27,190
Long-term Assets Other 107
Long-term Assets  (as reported)33,934
Long-term Assets  (calculated)33,934
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities31,125
Long-term Liabilities5,331
Total Stockholder Equity429,171
Total Current Liabilities
Short-term Debt 1,614
Accounts payable 3,494
Other Current Liabilities 26,017
Total Current Liabilities  (as reported)31,125
Total Current Liabilities  (calculated)31,125
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt928
Long-term Liabilities Other 4,403
Long-term Liabilities  (as reported)5,331
Long-term Liabilities  (calculated)5,331
+/-0
Total Stockholder Equity
Common Stock56
Retained Earnings -1,397,361
Accumulated Other Comprehensive Income 3,308
Other Stockholders Equity 1,823,168
Total Stockholder Equity (as reported)429,171
Total Stockholder Equity (calculated)429,171
+/-0
Other
Capital Stock56
Cash and Short Term Investments 421,698
Common Stock Shares Outstanding 52,028
Liabilities and Stockholders Equity 465,627
Net Debt -32,272
Net Invested Capital 429,171
Net Working Capital 400,568
Property Plant and Equipment Gross 29,022
Short Long Term Debt Total 2,542



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-311993-12-311993-09-301993-06-301993-03-311992-09-301992-06-301992-03-311991-12-311991-09-301991-06-301991-03-311990-12-311990-09-301990-06-301990-03-311989-12-311989-09-301989-06-301989-03-311988-12-311988-09-301988-06-301988-03-311987-12-311987-09-301987-06-301987-03-311986-12-311986-09-301986-06-301986-03-311985-12-311985-09-30
> Total Assets 
0
0
3,200
0
0
0
14,600
0
0
0
13,000
0
0
0
13,200
0
0
11,800
15,600
15,200
13,500
12,700
13,200
29,800
28,400
28,000
27,000
25,900
24,400
21,000
19,200
17,200
33,100
30,700
27,800
25,300
20,700
18,000
14,900
11,700
18,500
18,500
11,700
19,300
17,200
15,000
13,400
11,500
9,800
11,600
9,800
25,100
22,700
19,700
16,500
23,400
19,883
24,564
21,518
53,854
63,563
58,048
53,344
46,578
53,485
47,725
42,264
38,690
35,233
32,020
28,782
35,172
31,305
52,331
48,900
46,134
45,804
40,174
44,478
40,064
36,452
73,308
68,549
64,054
61,480
54,344
49,209
43,405
37,648
40,804
86,343
79,186
69,793
63,483
54,412
48,102
140,364
132,445
121,571
111,809
109,943
92,404
118,476
108,448
97,994
136,740
122,129
119,837
125,541
224,365
196,233
180,955
347,095
318,699
297,592
271,665
248,014
407,700
383,217
352,632
337,584
301,931
271,206
251,947
383,358
360,048
346,071
319,418
315,624
191,376
178,377
168,287
155,809
147,577
142,244
131,841
122,933
112,504
261,401
255,770
235,838
219,065
204,551
460,201
444,654
424,041
402,961
369,226
352,735
324,519
299,311
280,256
465,627
465,627280,256299,311324,519352,735369,226402,961424,041444,654460,201204,551219,065235,838255,770261,401112,504122,933131,841142,244147,577155,809168,287178,377191,376315,624319,418346,071360,048383,358251,947271,206301,931337,584352,632383,217407,700248,014271,665297,592318,699347,095180,955196,233224,365125,541119,837122,129136,74097,994108,448118,47692,404109,943111,809121,571132,445140,36448,10254,41263,48369,79379,18686,34340,80437,64843,40549,20954,34461,48064,05468,54973,30836,45240,06444,47840,17445,80446,13448,90052,33131,30535,17228,78232,02035,23338,69042,26447,72553,48546,57853,34458,04863,56353,85421,51824,56419,88323,40016,50019,70022,70025,1009,80011,6009,80011,50013,40015,00017,20019,30011,70018,50018,50011,70014,90018,00020,70025,30027,80030,70033,10017,20019,20021,00024,40025,90027,00028,00028,40029,80013,20012,70013,50015,20015,60011,8000013,20000013,00000014,6000003,20000
   > Total Current Assets 
0
0
2,800
0
0
0
14,000
0
0
0
11,600
0
0
0
10,700
0
0
9,200
12,700
12,400
10,800
10,000
10,600
27,100
25,800
25,300
24,200
23,000
21,300
17,700
15,700
13,600
29,500
27,200
23,800
21,300
17,700
15,100
12,000
7,700
13,600
13,600
7,400
15,100
13,300
12,600
11,000
9,000
7,400
9,100
6,700
16,300
15,600
12,800
10,100
17,600
14,490
19,699
16,946
49,566
51,807
46,769
42,412
35,912
43,343
37,762
32,478
29,145
25,860
20,921
18,035
24,782
22,309
43,444
40,201
36,615
34,540
28,894
33,089
28,593
24,605
61,250
54,992
48,163
42,403
33,925
27,329
21,380
16,413
22,677
69,026
55,561
47,076
41,839
33,509
28,010
83,976
78,283
68,251
59,200
62,947
46,228
73,289
64,382
54,684
94,236
80,398
78,810
85,114
184,453
156,430
139,946
305,189
276,819
255,597
229,825
204,985
364,129
339,541
309,256
294,936
260,955
228,782
209,714
195,569
173,463
160,052
147,317
144,756
130,972
120,280
110,969
99,079
88,851
84,365
75,103
66,698
55,918
208,992
202,925
197,843
181,499
167,606
426,555
410,839
390,699
367,979
334,599
317,693
289,597
264,820
245,933
431,693
431,693245,933264,820289,597317,693334,599367,979390,699410,839426,555167,606181,499197,843202,925208,99255,91866,69875,10384,36588,85199,079110,969120,280130,972144,756147,317160,052173,463195,569209,714228,782260,955294,936309,256339,541364,129204,985229,825255,597276,819305,189139,946156,430184,45385,11478,81080,39894,23654,68464,38273,28946,22862,94759,20068,25178,28383,97628,01033,50941,83947,07655,56169,02622,67716,41321,38027,32933,92542,40348,16354,99261,25024,60528,59333,08928,89434,54036,61540,20143,44422,30924,78218,03520,92125,86029,14532,47837,76243,34335,91242,41246,76951,80749,56616,94619,69914,49017,60010,10012,80015,60016,3006,7009,1007,4009,00011,00012,60013,30015,1007,40013,60013,6007,70012,00015,10017,70021,30023,80027,20029,50013,60015,70017,70021,30023,00024,20025,30025,80027,10010,60010,00010,80012,40012,7009,2000010,70000011,60000014,0000002,80000
       Cash And Cash Equivalents 
0
0
2,400
0
0
0
13,500
0
0
0
10,800
0
0
0
9,600
0
0
7,200
11,300
11,000
9,300
8,100
8,700
25,500
24,000
23,100
22,100
20,700
19,000
15,600
13,600
12,100
28,300
24,400
20,800
18,700
7,600
12,900
10,500
6,200
12,300
12,300
6,700
14,400
12,600
12,200
10,700
8,500
6,400
8,200
5,200
7,200
8,900
11,000
8,400
15,800
13,619
18,762
16,059
48,505
50,177
45,106
40,706
34,737
42,666
37,054
31,668
26,314
25,071
19,750
16,984
23,498
20,251
41,162
39,371
35,228
31,742
27,309
27,029
22,199
23,419
59,756
53,469
46,681
40,912
32,574
25,910
20,340
15,658
11,419
52,380
42,697
44,257
39,364
31,633
25,985
57,002
42,666
15,158
9,828
21,287
10,140
10,830
13,097
11,899
22,755
18,563
23,187
24,897
75,627
25,900
14,626
169,402
56,902
40,797
32,525
28,020
122,170
81,584
66,791
72,108
63,025
32,482
31,743
42,461
42,497
66,162
54,735
40,288
39,824
43,894
32,823
24,310
31,533
19,744
16,586
11,232
22,724
68,027
18,151
43,836
69,313
43,446
72,184
39,143
25,293
28,401
18,583
29,429
54,123
28,224
21,134
34,814
34,81421,13428,22454,12329,42918,58328,40125,29339,14372,18443,44669,31343,83618,15168,02722,72411,23216,58619,74431,53324,31032,82343,89439,82440,28854,73566,16242,49742,46131,74332,48263,02572,10866,79181,584122,17028,02032,52540,79756,902169,40214,62625,90075,62724,89723,18718,56322,75511,89913,09710,83010,14021,2879,82815,15842,66657,00225,98531,63339,36444,25742,69752,38011,41915,65820,34025,91032,57440,91246,68153,46959,75623,41922,19927,02927,30931,74235,22839,37141,16220,25123,49816,98419,75025,07126,31431,66837,05442,66634,73740,70645,10650,17748,50516,05918,76213,61915,8008,40011,0008,9007,2005,2008,2006,4008,50010,70012,20012,60014,4006,70012,30012,3006,20010,50012,9007,60018,70020,80024,40028,30012,10013,60015,60019,00020,70022,10023,10024,00025,5008,7008,1009,30011,00011,3007,200009,60000010,80000013,5000002,40000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,451
32,700
50,674
47,829
39,811
34,167
60,406
49,677
41,413
69,374
60,109
54,428
59,065
106,750
129,083
121,962
133,581
217,324
211,572
191,553
173,023
237,603
252,408
237,819
217,781
190,992
187,646
171,505
147,315
124,526
87,822
85,795
99,139
83,424
70,115
72,795
69,712
53,535
61,598
56,332
53,151
30,998
138,888
181,443
150,586
106,770
120,591
350,905
369,107
355,175
328,416
304,888
275,523
224,264
224,473
214,214
386,884
386,884214,214224,473224,264275,523304,888328,416355,175369,107350,905120,591106,770150,586181,443138,88830,99853,15156,33261,59853,53569,71272,79570,11583,42499,13985,79587,822124,526147,315171,505187,646190,992217,781237,819252,408237,603173,023191,553211,572217,324133,581121,962129,083106,75059,06554,42860,10969,37441,41349,67760,40634,16739,81147,82950,67432,70025,451000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
300
0
0
0
400
0
0
0
600
0
0
1,500
700
800
900
1,300
1,100
1,000
1,100
1,500
1,100
1,100
1,100
700
1,000
500
500
800
1,000
500
600
1,200
400
400
300
300
0
0
400
0
0
0
0
0
0
0
0
0
400
400
432
432
432
432
154
499
563
233
267
228
224
2,124
231
635
586
569
1,473
1,653
540
616
2,230
916
5,477
5,643
418
716
736
554
321
239
102
526
332
176
1,538
11,482
1,827
1,077
1,013
1,091
544
859
738
456
324
243
163
204
170
140
61
32
44
104
12
890
489
305
525
2,905
427
679
434
527
970
847
1,116
1,579
1,784
1,384
1,359
3,013
1,880
4,020
3,423
3,175
3,162
2,307
1,170
727
1,015
1,108
329
838
1,802
1,828
496
197
172
243
97
189
347
1,314
118
252
4,528
4,5282521181,314347189972431721974961,8281,8028383291,1081,0157271,1702,3073,1623,1753,4234,0201,8803,0131,3591,3841,7841,5791,1168479705274346794272,905525305489890121044432611401702041632433244567388595441,0911,0131,0771,82711,4821,5381763325261022393215547367164185,6435,4779162,2306165401,6531,4735695866352312,124224228267233563499154432432432432400400000000000400003003004004001,2006005001,0008005005001,0007001,1001,1001,1001,5001,1001,0001,1001,3009008007001,50000600000400000300000000
       Other Current Assets 
0
0
400
0
0
0
200
0
0
0
300
0
0
0
300
0
0
100
300
400
200
200
500
200
300
200
400
700
700
800
600
400
300
1,500
1,500
1,600
9,100
600
600
600
600
600
700
700
300
400
300
500
1,000
900
1,500
9,100
6,700
1,800
1,300
1,400
439
506
456
630
1,417
1,114
1,057
863
339
421
539
706
558
537
465
715
585
630
290
771
568
669
583
751
767
778
788
927
1,171
1,112
1,317
515
423
11,082
15,108
1,382
992
1,397
863
934
979
2,058
1,681
1,087
1,525
1,678
1,890
1,404
1,202
1,967
1,665
1,163
1,152
2,076
1,435
2,468
1,717
2,288
3,228
5,747
3,942
4,356
5,115
4,119
5,047
6,091
7,538
6,466
5,793
5,056
4,709
3,774
3,449
3,704
2,848
2,176
5,057
1,476
1,853
1,458
2,315
1,088
1,748
2,493
3,421
3,588
3,073
3,269
2,589
9,988
11,065
10,939
12,741
11,210
12,123
10,333
5,467
5,46710,33312,12311,21012,74110,93911,0659,9882,5893,2693,0733,5883,4212,4931,7481,0882,3151,4581,8531,4765,0572,1762,8483,7043,4493,7744,7095,0565,7936,4667,5386,0915,0474,1195,1154,3563,9425,7473,2282,2881,7172,4681,4352,0761,1521,1631,6651,9671,2021,4041,8901,6781,5251,0871,6812,0589799348631,3979921,38215,10811,0824235151,3171,1121,1719277887787677515836695687712906305857154655375587065394213398631,0571,1141,4176304565064391,4001,3001,8006,7009,1001,5009001,0005003004003007007006006006006006009,1001,6001,5001,5003004006008007007004002003002005002002004003001000030000030000020000040000
   > Long-term Assets 
0
0
400
0
0
0
600
0
0
0
1,400
0
0
0
2,500
0
0
2,600
2,900
2,800
2,700
2,700
2,600
2,700
2,600
2,700
2,800
2,900
3,100
3,300
3,500
3,600
3,600
3,500
4,000
4,000
3,000
2,900
2,900
4,000
4,900
4,900
4,300
4,200
3,900
2,400
2,400
2,500
2,400
2,500
3,100
8,800
7,100
6,900
6,400
5,800
5,393
4,864
4,572
4,287
11,756
11,279
10,932
10,666
10,141
9,963
9,786
9,545
9,373
11,099
10,747
10,390
8,996
8,888
8,699
9,519
11,264
11,280
11,389
11,471
11,847
12,058
13,556
15,891
19,076
20,419
21,880
22,024
21,236
18,127
17,317
23,625
22,717
21,644
20,903
20,092
56,388
54,162
53,320
52,609
46,996
46,176
45,187
44,066
43,310
42,504
41,731
41,027
40,427
39,912
39,803
41,009
41,906
41,880
41,995
41,840
43,029
43,571
43,676
43,376
42,648
40,976
42,424
42,233
187,789
186,585
186,019
172,101
170,868
60,404
58,097
57,318
56,730
58,726
57,879
56,738
56,235
56,586
52,409
52,845
37,995
37,566
36,945
33,646
33,815
33,342
34,982
34,627
35,042
34,922
34,491
34,323
33,934
33,93434,32334,49134,92235,04234,62734,98233,34233,81533,64636,94537,56637,99552,84552,40956,58656,23556,73857,87958,72656,73057,31858,09760,404170,868172,101186,019186,585187,78942,23342,42440,97642,64843,37643,67643,57143,02941,84041,99541,88041,90641,00939,80339,91240,42741,02741,73142,50443,31044,06645,18746,17646,99652,60953,32054,16256,38820,09220,90321,64422,71723,62517,31718,12721,23622,02421,88020,41919,07615,89113,55612,05811,84711,47111,38911,28011,2649,5198,6998,8888,99610,39010,74711,0999,3739,5459,7869,96310,14110,66610,93211,27911,7564,2874,5724,8645,3935,8006,4006,9007,1008,8003,1002,5002,4002,5002,4002,4003,9004,2004,3004,9004,9004,0002,9002,9003,0004,0004,0003,5003,6003,6003,5003,3003,1002,9002,8002,7002,6002,7002,6002,7002,7002,8002,9002,600002,5000001,40000060000040000
       Property Plant Equipment 
0
0
400
0
0
0
600
0
0
0
900
0
0
0
2,000
0
0
2,100
2,200
2,100
2,100
2,100
2,000
1,900
1,900
1,900
1,900
2,100
2,000
2,000
2,000
2,000
1,800
1,800
2,200
2,200
1,100
800
800
1,300
1,200
1,200
500
500
500
500
400
400
400
300
300
1,100
1,100
1,500
1,500
1,300
1,257
1,166
1,073
990
1,038
969
977
1,084
988
1,029
1,076
1,038
1,120
1,114
1,069
973
913
1,053
1,113
2,172
4,164
4,430
4,789
5,119
5,744
6,204
7,950
10,534
13,968
15,551
16,555
17,073
16,441
14,593
14,033
14,191
13,567
13,016
12,551
12,015
11,489
10,965
10,972
10,924
10,832
10,472
9,985
9,539
9,093
8,447
7,998
7,566
7,205
7,131
7,338
8,814
9,973
10,216
10,601
10,716
10,535
11,236
11,735
11,864
11,461
11,392
11,293
11,355
13,192
12,411
12,069
11,308
10,372
9,785
7,478
6,699
6,111
9,907
9,060
7,919
4,031
7,855
7,178
7,614
3,815
6,835
6,214
6,358
3,551
6,048
7,688
7,333
3,747
3,995
3,938
7,026
6,637
6,6377,0263,9383,9953,7477,3337,6886,0483,5516,3586,2146,8353,8157,6147,1787,8554,0317,9199,0609,9076,1116,6997,4789,78510,37211,30812,06912,41113,19211,35511,29311,39211,46111,86411,73511,23610,53510,71610,60110,2169,9738,8147,3387,1317,2057,5667,9988,4479,0939,5399,98510,47210,83210,92410,97210,96511,48912,01512,55113,01613,56714,19114,03314,59316,44117,07316,55515,55113,96810,5347,9506,2045,7445,1194,7894,4304,1642,1721,1131,0539139731,0691,1141,1201,0381,0761,0299881,0849779691,0389901,0731,1661,2571,3001,5001,5001,1001,1003003004004004005005005005001,2001,2001,3008008001,1002,2002,2001,8001,8002,0002,0002,0002,0002,1001,9001,9001,9001,9002,0002,1002,1002,1002,2002,100002,00000090000060000040000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,036
1,036
1,036
0
1,036
1,036
1,036
1,036,300
1,036
1,036
1,036
1,036,300
1,036
1,036
1,036
1,036,285
1,036
1,036
1,036
1,036
1,036
1,036
1,036
1,036
1,036
0
0
0
0
0
0
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
8,965
90,976
90,976
90,976
90,976
90,976
90,976
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,363
0
0
003,3630000000000000000000090,97690,97690,97690,97690,97690,9768,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9658,9650000001,0361,0361,0361,0361,0361,0361,0361,0361,0361,036,2851,0361,0361,0361,036,3001,0361,0361,0361,036,3001,0361,0361,03601,0361,0361,03600000000000000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,800000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,000
0
0
0
0
0
0
0
0
10,719
1,375
9,955
9,582
9,154
8,849
8,625
8,422
8,169
9,985
9,594
9,332
7,999
7,835
7,586
7,347
7,100
6,850
6,506
6,352
6,103
4,818
4,570
4,226
3,977
3,832
3,592
3,257
3,112
2,785
2,680
2,576
2,472
2,132
2,036
1,941
29,979
28,459
27,801
41,685
26,836
26,353
35,202
34,527
24,923
34,057
33,733
33,461
33,222
32,781
23,326
23,073
22,820
22,567
31,394
31,124
32,494
32,335
21,300
21,047
31,187
20,541
20,287
30,878
174,597
81,263
81,039
67,815
67,591
48,690
48,690
48,690
50,619
48,690
48,690
48,690
52,204
48,690
45,190
45,190
34,180
30,690
30,690
27,190
30,264
27,190
27,190
27,190
31,295
30,927
27,190
27,190
27,190
27,19027,19027,19030,92731,29527,19027,19027,19030,26427,19030,69030,69034,18045,19045,19048,69052,20448,69048,69048,69050,61948,69048,69048,69067,59167,81581,03981,263174,59730,87820,28720,54131,18721,04721,30032,33532,49431,12431,39422,56722,82023,07323,32632,78133,22233,46133,73334,05724,92334,52735,20226,35326,83641,68527,80128,45929,9791,9412,0362,1322,4722,5762,6802,7853,1123,2573,5923,8323,9774,2264,5704,8186,1036,3526,5066,8507,1007,3477,5867,8357,9999,3329,5949,9858,1698,4228,6258,8499,1549,5829,9551,37510,719000000004,000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,600
0
0
0
1,327
0
0
1,241
4,795
3,534
3,284
9,433
9,149
8,628
8,352
8,077
44,899
43,197
42,348
41,685
36,164
35,704
35,202
34,527
34,217
34,057
33,733
33,461
33,222
32,781
32,465
32,195
31,933
31,664
31,394
31,124
32,494
32,335
31,941
31,512
31,187
29,584
31,131
30,878
174,597
174,174
173,950
160,793
160,496
1,929
1,929
1,929
129
129
129
129
41
41
41
41
41
41
41
98
104
104
104
104
104
0
107
0
0
00107010410410410410498414141414141411291291291291,9291,9291,929160,496160,793173,950174,174174,59730,87831,13129,58431,18731,51231,94132,33532,49431,12431,39431,66431,93332,19532,46532,78133,22233,46133,73334,05734,21734,52735,20235,70436,16441,68542,34843,19744,8998,0778,3528,6289,1499,4333,2843,5344,7951,241001,3270001,60000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
5,700
0
0
0
4,200
0
0
0
3,700
0
0
0
4,800
0
0
1,900
2,500
3,100
2,100
2,100
2,800
2,800
2,900
2,800
3,400
3,400
3,100
2,700
2,500
2,900
4,000
4,200
4,100
4,500
3,100
2,800
2,300
2,000
2,500
2,500
1,500
1,300
1,600
1,300
1,400
3,800
3,500
3,000
2,700
4,000
3,900
3,700
2,800
2,400
2,470
5,427
4,867
5,753
9,631
7,832
8,639
8,038
8,216
7,335
7,038
3,777
3,889
4,120
4,071
3,248
3,385
2,941
3,329
4,155
7,396
6,512
15,429
15,376
15,563
55,120
55,750
56,355
59,319
57,708
58,041
57,351
56,692
12,641
56,909
55,348
51,660
51,693
50,109
50,342
66,597
63,986
61,569
59,788
34,688
26,619
26,471
27,774
29,272
28,854
27,581
28,822
29,767
29,424
19,139
24,210
27,300
26,853
32,277
32,293
36,354
32,148
37,339
34,005
47,479
41,899
36,497
34,855
117,927
112,212
114,614
100,266
79,255
57,294
50,330
40,153
31,749
34,884
32,618
30,461
28,907
28,801
22,957
25,795
26,481
24,899
22,269
23,489
25,178
25,940
37,868
23,810
26,531
21,779
21,774
33,538
36,456
36,45633,53821,77421,77926,53123,81037,86825,94025,17823,48922,26924,89926,48125,79522,95728,80128,90730,46132,61834,88431,74940,15350,33057,29479,255100,266114,614112,212117,92734,85536,49741,89947,47934,00537,33932,14836,35432,29332,27726,85327,30024,21019,13929,42429,76728,82227,58128,85429,27227,77426,47126,61934,68859,78861,56963,98666,59750,34250,10951,69351,66055,34856,90912,64156,69257,35158,04157,70859,31956,35555,75055,12015,56315,37615,4296,5127,3964,1553,3292,9413,3853,2484,0714,1203,8893,7777,0387,3358,2168,0388,6397,8329,6315,7534,8675,4272,4702,4002,8003,7003,9004,0002,7003,0003,5003,8001,4001,3001,6001,3001,5002,5002,5002,0002,3002,8003,1004,5004,1004,2004,0002,9002,5002,7003,1003,4003,4002,8002,9002,8002,8002,1002,1003,1002,5001,900004,8000003,7000004,2000005,70000
   > Total Current Liabilities 
0
0
500
0
0
0
1,700
0
0
0
1,300
0
0
0
2,500
0
0
1,900
2,500
3,100
2,100
2,100
2,800
2,800
2,800
2,800
3,400
3,400
3,100
2,700
2,500
2,900
3,400
3,700
3,700
4,000
2,600
2,400
2,100
1,800
2,400
2,400
1,400
1,100
1,600
1,400
1,400
2,300
2,800
2,200
1,900
2,800
3,300
3,100
2,400
2,000
2,201
2,308
1,979
3,092
5,398
3,984
5,175
4,960
5,523
5,027
5,114
3,623
3,433
3,788
3,864
3,166
3,385
2,941
3,329
3,812
5,451
4,598
3,577
3,586
3,693
6,513
6,595
8,231
10,084
10,208
8,465
8,762
9,833
11,479
20,156
18,424
14,102
14,052
12,856
14,107
14,407
24,824
23,714
23,281
20,208
8,920
10,409
10,778
14,298
12,546
12,579
15,131
17,685
18,330
12,503
16,795
20,350
19,507
21,202
21,614
24,491
21,148
26,691
23,635
30,240
25,307
20,003
18,630
35,223
27,024
28,788
24,915
27,736
24,012
19,982
16,851
12,602
11,989
11,509
11,888
11,643
10,932
10,841
12,200
14,206
16,977
14,488
14,176
16,528
14,560
29,949
16,287
18,610
15,219
15,646
27,836
31,125
31,12527,83615,64615,21918,61016,28729,94914,56016,52814,17614,48816,97714,20612,20010,84110,93211,64311,88811,50911,98912,60216,85119,98224,01227,73624,91528,78827,02435,22318,63020,00325,30730,24023,63526,69121,14824,49121,61421,20219,50720,35016,79512,50318,33017,68515,13112,57912,54614,29810,77810,4098,92020,20823,28123,71424,82414,40714,10712,85614,05214,10218,42420,15611,4799,8338,7628,46510,20810,0848,2316,5956,5133,6933,5863,5774,5985,4513,8123,3292,9413,3853,1663,8643,7883,4333,6235,1145,0275,5234,9605,1753,9845,3983,0921,9792,3082,2012,0002,4003,1003,3002,8001,9002,2002,8002,3001,4001,4001,6001,1001,4002,4002,4001,8002,1002,4002,6004,0003,7003,7003,4002,9002,5002,7003,1003,4003,4002,8002,8002,8002,8002,1002,1003,1002,5001,900002,5000001,3000001,70000050000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
800
800
800
1,000
1,000
800
1,000
294
294
294
294
275
200
125
50
0
0
0
0
0
0
0
0
0
0
0
0
3,500
3,238
2,721
2,892
217
210
3,085
2,625
478
546
576
3,039
580
162
164
166
161
213
221
229
2,156
14,253
13,222
13,306
1,111
3,333
5,000
4,091
6,355
5,652
5,629
5,693
5,592
5,630
0
0
0
0
0
0
2,592
2,657
0
0
4,418
4,239
4,360
4,378
4,826
4,940
5,538
5,792
6,566
6,566
0
4,688
4,526
2,633
2,538
2,253
1,944
1,682
1,320
1,263
1,327
1,372
1,331
1,366
1,746
1,802
1,425
1,438
1,445
1,493
1,530
1,547
1,614
1,6141,5471,5301,4931,4451,4381,4251,8021,7461,3661,3311,3721,3271,2631,3201,6821,9442,2532,5382,6334,5264,68806,5666,5665,7925,5384,9404,8264,3784,3604,2394,418002,6572,5920000005,6305,5925,6935,6295,6526,3554,0915,0003,3331,11113,30613,22214,2532,1562292212131611661641625803,0395765464782,6253,0852102172,8922,7213,2383,500000000000000501252002752942942942941,0008001,0001,000800800800800000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,592
0
0
0
4,418
4,239
4,360
4,378
4,826
4,940
5,538
5,792
6,566
8,607
0
0
4,526
2,633
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,6334,526008,6076,5665,7925,5384,9404,8264,3784,3604,2394,4180002,59200000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
400
800
500
400
500
500
300
400
0
200
100
300
300
300
600
500
700
900
600
800
800
1,100
800
700
700
200
100
300
300
300
300
200
200
300
200
400
700
100
100
575
362
256
722
902
382
613
873
1,130
258
592
497
836
349
187
259
476
427
308
650
1,752
1,136
617
477
1,141
599
661
831
2,552
1,018
888
1,023
1,262
1,880
1,329
1,406
2,153
4,455
4,332
4,110
1,445
1,617
1,073
741
931
738
514
457
935
535
395
1,281
745
2,451
2,069
1,982
2,243
3,414
1,187
1,720
2,603
3,071
2,020
1,217
1,506
2,637
706
1,019
1,740
2,660
1,975
1,278
1,715
508
2,942
2,311
1,069
1,105
1,016
666
1,174
1,609
950
568
1,048
997
685
836
1,228
1,019
902
2,272
3,340
3,374
881
3,586
3,494
3,4943,5868813,3743,3402,2729021,0191,2288366859971,0485689501,6091,1746661,0161,1051,0692,3112,9425081,7151,2781,9752,6601,7401,0197062,6371,5061,2172,0203,0712,6031,7201,1873,4142,2431,9822,0692,4517451,2813955359354575147389317411,0731,6171,4454,1104,3324,4552,1531,4061,3291,8801,2621,0238881,0182,5528316615991,1414776171,1361,7526503084274762591873498364975922581,1308736133829027222563625751001007004002003002002003003003003001002007007008001,100800800600900700500600300300300100200040030050050040050080040000000000000000000
       Other Current Liabilities 
0
0
500
0
0
0
1,700
0
0
0
1,300
0
0
0
2,500
0
0
1,500
1,700
2,600
1,700
1,600
2,300
2,500
2,400
0
3,200
3,300
2,800
2,400
2,200
2,300
2,900
3,000
2,800
3,400
1,800
1,600
1,000
1,000
1,700
1,700
1,200
1,000
1,300
1,100
1,100
2,000
1,800
1,200
800
1,800
1,900
1,400
1,500
900
1,332
1,652
1,429
2,076
4,221
1,780
2,815
2,414
2,733
3,120
2,886
2,119
2,099
1,904
2,154
2,396
1,453
2,132
2,764
3,029
187
187
214
205
-9,997,665
2,858
231
223
2,675
2,604
3,216
578
3,146
8,344
13,530
11,810
6,856
4,359
3,024
4,402
5,615
3,810
4,134
4,178
13,230
649
479
264
7,008
6,359
6,555
8,157
388
557
10,434
14,813
18,107
16,093
20,015
19,894
2,592
2,657
24,671
22,418
4,418
22,670
4,360
4,378
33,483
24,364
26,813
23,637
6,566
23,504
17,040
4,926
4,526
2,777
2,545
2,550
2,026
1,993
2,104
2,362
3,372
7,585
4,621
1,721
1,554
11,739
27,622
12,577
13,825
10,352
978
4,232
26,017
26,0174,23297810,35213,82512,57727,62211,7391,5541,7214,6217,5853,3722,3622,1041,9932,0262,5502,5452,7774,5264,92617,04023,5046,56623,63726,81324,36433,4834,3784,36022,6704,41822,41824,6712,6572,59219,89420,01516,09318,10714,81310,4345573888,1576,5556,3597,00826447964913,2304,1784,1343,8105,6154,4023,0244,3596,85611,81013,5308,3443,1465783,2162,6042,6752232312,858-9,997,6652052141871873,0292,7642,1321,4532,3962,1541,9042,0992,1192,8863,1202,7332,4142,8151,7804,2212,0761,4291,6521,3329001,5001,4001,9001,8008001,2001,8002,0001,1001,1001,3001,0001,2001,7001,7001,0001,0001,6001,8003,4002,8003,0002,9002,3002,2002,4002,8003,3003,20002,4002,5002,3001,6001,7002,6001,7001,500002,5000001,3000001,70000050000
   > Long-term Liabilities 
0
0
5,200
0
0
0
2,500
0
0
0
2,400
0
0
0
2,300
0
0
400
800
500
400
500
500
300
100
0
200
100
300
300
300
600
600
500
400
500
500
400
200
200
100
100
100
200
300
-100
300
1,500
700
800
800
1,200
600
600
400
400
269
3,119
2,888
2,661
4,233
3,848
3,463
3,078
2,693
2,309
1,924
154
456
332
207
83
1,932
809
565
343
1,945
1,914
11,852
11,791
11,870
48,607
49,154
48,123
49,234
47,501
49,575
48,589
46,859
1,162
36,754
36,923
37,558
37,641
37,253
36,235
52,190
39,162
37,855
36,507
14,480
17,699
16,062
16,996
14,974
16,308
15,002
13,691
12,082
11,094
6,636
7,415
6,950
7,346
11,075
10,679
11,863
11,000
10,648
10,370
17,239
16,592
16,494
16,225
82,704
85,188
85,826
75,351
51,519
33,282
30,348
23,302
19,147
22,895
21,109
18,573
17,264
17,869
12,116
13,595
12,275
7,922
7,781
9,313
8,650
11,380
7,919
7,523
7,921
6,560
6,128
5,702
5,331
5,3315,7026,1286,5607,9217,5237,91911,3808,6509,3137,7817,92212,27513,59512,11617,86917,26418,57321,10922,89519,14723,30230,34833,28251,51975,35185,82685,18882,70416,22516,49416,59217,23910,37010,64811,00011,86310,67911,0757,3466,9507,4156,63611,09412,08213,69115,00216,30814,97416,99616,06217,69914,48036,50737,85539,16252,19036,23537,25337,64137,55836,92336,7541,16246,85948,58949,57547,50149,23448,12349,15448,60711,87011,79111,8521,9141,9453435658091,932832073324561541,9242,3092,6933,0783,4633,8484,2332,6612,8883,1192694004006006001,2008008007001,500300-1003002001001001002002004005005004005006006003003003001002000100300500500400500800400002,3000002,4000002,5000005,20000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,068
11,015
9,008
9,890
8,608
7,326
5,746
4,426
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000004,4265,7467,3268,6089,8909,00811,01510,068000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,152
0
0
0
914
0
0
501
45,361
254
35,906
36,137
36,732
36,860
37,253
36,235
35,215
39,162
37,855
36,507
404
1,341
1,333
1,320
829
1,757
1,733
1,704
1,256
2,007
1,975
2,754
2,289
2,685
6,414
6,018
7,202
6,339
5,987
5,709
12,578
11,931
11,833
11,564
54,650
57,134
57,772
52,497
47,747
33,282
30,348
23,302
19,147
20,296
19,242
17,091
15,551
15,763
10,396
11,050
10,121
6,158
6,335
7,600
7,354
10,539
5,333
5,333
5,333
0
6,128
0
0
006,12805,3335,3335,33310,5397,3547,6006,3356,15810,12111,05010,39615,76315,55117,09119,24220,29619,14723,30230,34833,28247,74752,49757,77257,13454,65011,56411,83311,93112,5785,7095,9876,3397,2026,0186,4142,6852,2892,7541,9752,0071,2561,7041,7331,7578291,3201,3331,34140436,50737,85539,16235,21536,23537,25336,86036,73236,13735,90625445,361501009140001,15200000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
-2,500
0
0
0
10,400
0
0
0
9,300
0
0
0
8,400
0
0
9,900
13,100
12,100
11,400
10,600
10,400
26,300
24,800
24,600
23,100
22,000
20,900
18,200
16,700
14,300
29,100
26,500
23,700
20,800
17,600
15,200
12,600
9,700
16,000
16,000
10,200
18,000
15,600
13,700
12,000
7,700
6,300
8,600
7,100
21,100
18,800
16,000
13,700
21,000
17,413
19,137
16,651
48,101
53,932
50,216
44,706
38,540
45,269
40,390
35,226
34,913
31,344
27,900
24,711
31,923
27,920
49,390
45,571
41,979
38,408
33,663
29,050
24,688
20,889
18,189
12,799
7,700
2,161
-3,365
-8,831
-13,947
-19,044
28,163
29,433
23,838
18,134
11,790
4,303
-2,240
73,767
68,459
60,002
52,021
75,255
65,785
92,005
80,674
68,722
107,886
94,548
91,015
95,774
194,941
177,094
156,745
319,795
291,846
265,315
239,372
211,660
375,552
345,878
318,627
290,105
260,032
234,709
217,092
265,431
247,836
231,457
219,152
236,369
134,082
128,047
128,134
124,060
112,693
109,626
101,380
94,026
83,703
238,444
229,975
209,357
194,166
182,282
436,712
419,476
398,101
365,093
345,416
326,204
302,740
277,537
246,718
429,171
429,171246,718277,537302,740326,204345,416365,093398,101419,476436,712182,282194,166209,357229,975238,44483,70394,026101,380109,626112,693124,060128,134128,047134,082236,369219,152231,457247,836265,431217,092234,709260,032290,105318,627345,878375,552211,660239,372265,315291,846319,795156,745177,094194,94195,77491,01594,548107,88668,72280,67492,00565,78575,25552,02160,00268,45973,767-2,2404,30311,79018,13423,83829,43328,163-19,044-13,947-8,831-3,3652,1617,70012,79918,18920,88924,68829,05033,66338,40841,97945,57149,39027,92031,92324,71127,90031,34434,91335,22640,39045,26938,54044,70650,21653,93248,10116,65119,13717,41321,00013,70016,00018,80021,1007,1008,6006,3007,70012,00013,70015,60018,00010,20016,00016,0009,70012,60015,20017,60020,80023,70026,50029,10014,30016,70018,20020,90022,00023,10024,60024,80026,30010,40010,60011,40012,10013,1009,900008,4000009,30000010,400000-2,50000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48
50
50
55
57
57
57
57
60
61
61
61
61
61
61
65
65
74
74
74
74
74
74
74
74
74
74
74
74
74
74
74
6
15
16
16
16
16
16
16
32
32
32
32
32
32
44
44
44
59
59
61
64
81
81
81
89
89
89
89
90
98
99
99
99
99
99
101
121
124
127
132
139
143
157
169
12
13
15
16
17
18
39
40
40
40
40
47
47
47
47
47
47
47
47
47
56
564747474747474747474040404039181716151312169157143139132127124121101999999999998908989898981818164615959444444323232323232161616161616156747474747474747474747474747474656561616161616160575757575550504800000000000000000000000000000000000000000000000000000000
   Retained Earnings Total Equity00-1,315,795-1,285,2930-1,229,445-1,202,661-1,166,657-1,143,607-1,123,459-1,103,007-1,089,634-1,073,096-1,051,196-1,036,972-1,025,941-1,013,316-1,002,869-991,456-979,677-962,438-953,036-945,792-929,388-812,517-808,676-782,313-753,747-719,486-687,179-657,581-625,629-590,956-558,272-526,292-493,933-463,759-431,937-403,856-375,582-345,679-323,617-300,477-281,461-264,129-247,322-232,295-218,522-205,006-192,274-180,502000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-100
0
0
0
-200
0
0
0
-500
0
0
0
-700
0
0
-700
-1,200
-1,200
-1,200
-1,200
-1,700
-1,700
-1,700
-1,700
-2,200
-2,200
-2,200
-2,700
-2,700
-2,700
-3,300
-3,300
-3,300
-3,300
-3,000
-3,000
-3,000
-3,000
-3,200
-3,200
-2,300
-2,300
-2,500
-2,600
-2,600
-2,700
-2,700
-2,800
-2,800
-4,200
-2,900
-3,000
-3,100
-3,300
-3,454
-3,590
-3,726
-3,845
-4,080
-4,216
-4,080
-4,080
-3,958
-4,102
-4,211
-4,300
-4,394
-4,500
-4,603
-1,058
-989
-228
-851
-782
-1,493
-1,372
-1,251
-1,400
-1,225
-5,866
-6,107
-5,155
-5,369
-5,559
-5,976
-6,260
70
2,508
2,355
2,569
2,606
2,594
2,591
2,593
2,546
2,663
2,658
2,796
2,751
2,760
2,774
2,654
2,652
2,762
2,722
2,775
2,745
2,689
2,548
2,686
2,668
2,670
2,748
2,624
2,590
2,616
2,436
2,560
2,307
2,687
2,723
2,610
2,541
2,562
2,577
2,588
2,564
2,559
2,590
2,582
2,583
2,602
2,638
2,635
2,619
2,597
2,594
2,608
2,589
2,587
2,592
2,548
1,894
112
-417
-112
1,260
2,123
2,072
2,135
3,308
3,3082,1352,0722,1231,260-112-4171121,8942,5482,5922,5872,5892,6082,5942,5972,6192,6352,6382,6022,5832,5822,5902,5592,5642,5882,5772,5622,5412,6102,7232,6872,3072,5602,4362,6162,5902,6242,7482,6702,6682,6862,5482,6892,7452,7752,7222,7622,6522,6542,7742,7602,7512,7962,6582,6632,5462,5932,5912,5942,6062,5692,3552,50870-6,260-5,976-5,559-5,369-5,155-6,107-5,866-1,225-1,400-1,251-1,372-1,493-782-851-228-989-1,058-4,603-4,500-4,394-4,300-4,211-4,102-3,958-4,080-4,080-4,216-4,080-3,845-3,726-3,590-3,454-3,300-3,100-3,000-2,900-4,200-2,800-2,800-2,700-2,700-2,600-2,600-2,500-2,300-2,300-3,200-3,200-3,000-3,000-3,000-3,000-3,300-3,300-3,300-3,300-2,700-2,700-2,700-2,200-2,200-2,200-1,700-1,700-1,700-1,700-1,200-1,200-1,200-1,200-70000-700000-500000-200000-10000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
269,689
270,250
271,032
323,587
324,062
335,501
357,094
473,632
474,942
477,595
662,717
664,669
666,334
668,596
672,739
866,771
869,635
874,240
878,655
882,875
889,468
901,560
982,255
998,897
1,011,066
1,025,108
1,046,183
1,060,768
1,071,092
1,078,419
1,083,903
1,089,755
1,098,429
1,101,598
1,104,706
1,107,029
1,272,783
1,278,523
1,279,824
1,281,173
1,282,657
1,557,576
1,561,142
1,564,599
1,568,124
1,574,926
0
1,585,863
1,591,213
0
0
001,591,2131,585,86301,574,9261,568,1241,564,5991,561,1421,557,5761,282,6571,281,1731,279,8241,278,5231,272,7831,107,0291,104,7061,101,5981,098,4291,089,7551,083,9031,078,4191,071,0921,060,7681,046,1831,025,1081,011,066998,897982,255901,560889,468882,875878,655874,240869,635866,771672,739668,596666,334664,669662,717477,595474,942473,632357,094335,501324,062323,587271,032270,250269,689000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000-2280000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
500
0
0
0
14,300
0
0
0
14,700
0
0
0
15,100
0
0
16,200
19,600
20,500
20,800
20,800
22,300
38,000
38,000
37,200
38,200
38,300
38,300
41,300
41,400
41,300
58,900
58,200
57,700
57,800
58,700
58,700
58,700
58,900
65,500
65,500
65,000
75,100
75,200
75,400
75,300
79,200
79,200
83,100
82,900
145,000
143,700
143,800
143,900
154,000
154,164
158,146
158,519
193,717
213,276
213,699
213,723
213,781
227,240
227,419
227,527
227,580
227,581
227,604
227,702
233,480
233,416
256,025
256,728
256,764
257,602
257,605
257,605
257,907
257,912
262,823
263,345
262,815
263,702
263,992
264,448
264,871
258,765
121,419
133,102
134,949
136,661
138,034
139,253
139,882
228,863
230,020
231,093
232,061
232,679
233,259
269,689
270,250
271,032
323,587
324,062
335,501
357,094
473,632
474,942
477,595
662,717
664,669
666,334
668,596
672,739
866,771
869,635
874,240
878,655
882,875
889,468
901,560
982,255
998,897
1,011,066
1,025,108
1,046,183
1,060,768
1,071,092
1,078,419
1,083,903
1,089,755
1,098,429
1,101,598
1,104,706
1,107,029
1,272,783
1,278,523
1,279,824
1,281,173
1,282,657
1,557,576
1,561,142
1,564,599
1,568,124
1,574,926
1,580,829
1,585,863
1,591,213
1,598,591
1,823,168
1,823,1681,598,5911,591,2131,585,8631,580,8291,574,9261,568,1241,564,5991,561,1421,557,5761,282,6571,281,1731,279,8241,278,5231,272,7831,107,0291,104,7061,101,5981,098,4291,089,7551,083,9031,078,4191,071,0921,060,7681,046,1831,025,1081,011,066998,897982,255901,560889,468882,875878,655874,240869,635866,771672,739668,596666,334664,669662,717477,595474,942473,632357,094335,501324,062323,587271,032270,250269,689233,259232,679232,061231,093230,020228,863139,882139,253138,034136,661134,949133,102121,419258,765264,871264,448263,992263,702262,815263,345262,823257,912257,907257,605257,605257,602256,764256,728256,025233,416233,480227,702227,604227,581227,580227,527227,419227,240213,781213,723213,699213,276193,717158,519158,146154,164154,000143,900143,800143,700145,00082,90083,10079,20079,20075,30075,40075,20075,10065,00065,50065,50058,90058,70058,70058,70057,80057,70058,20058,90041,30041,40041,30038,30038,30038,20037,20038,00038,00022,30020,80020,80020,50019,60016,2000015,10000014,70000014,30000050000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue6,883
Cost of Revenue-3,008
Gross Profit3,8753,875
 
Operating Income (+$)
Gross Profit3,875
Operating Expense-145,917
Operating Income-142,042-142,042
 
Operating Expense (+$)
Research Development115,003
Selling General Administrative30,914
Selling And Marketing Expenses0
Operating Expense145,917145,917
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-142,042
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-141,429-142,655
EBIT - interestExpense = -142,042
-141,429
-141,429
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-142,042-141,429
Earnings Before Interest and Taxes (EBITDA)-139,034
 
After tax Income (+$)
Income Before Tax-141,429
Tax Provision-0
Net Income From Continuing Ops-124,610-141,429
Net Income-141,429
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses148,925
Total Other Income/Expenses Net6130
 

Technical Analysis of Celldex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Celldex. The general trend of Celldex is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Celldex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Celldex Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 41.67 < 53.18.

The bearish price targets are: 35.03 > 34.65 > 33.55.

Tweet this
Celldex Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Celldex Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Celldex Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Celldex Therapeutics Inc. The current macd is -1.26452425.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Celldex price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Celldex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Celldex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Celldex Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCelldex Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Celldex Therapeutics Inc. The current adx is 10.05.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Celldex shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Celldex Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Celldex Therapeutics Inc. The current sar is 40.76.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Celldex Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Celldex Therapeutics Inc. The current rsi is 35.06. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Celldex Therapeutics Inc Daily Relative Strength Index (RSI) ChartCelldex Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Celldex Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Celldex price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Celldex Therapeutics Inc Daily Stochastic Oscillator ChartCelldex Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Celldex Therapeutics Inc. The current cci is -193.0186834.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Celldex Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCelldex Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Celldex Therapeutics Inc. The current cmo is -39.52828881.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Celldex Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCelldex Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Celldex Therapeutics Inc. The current willr is -93.11531842.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Celldex Therapeutics Inc Daily Williams %R ChartCelldex Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Celldex Therapeutics Inc.

Celldex Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Celldex Therapeutics Inc. The current atr is 1.76363192.

Celldex Therapeutics Inc Daily Average True Range (ATR) ChartCelldex Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Celldex Therapeutics Inc. The current obv is -13,768,892.

Celldex Therapeutics Inc Daily On-Balance Volume (OBV) ChartCelldex Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Celldex Therapeutics Inc. The current mfi is 31.88.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Celldex Therapeutics Inc Daily Money Flow Index (MFI) ChartCelldex Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Celldex Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Celldex Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Celldex Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.057
Ma 20Greater thanMa 5039.383
Ma 50Greater thanMa 10041.968
Ma 100Greater thanMa 20039.625
OpenGreater thanClose36.290
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Celldex with someone you think should read this too:
  • Are you bullish or bearish on Celldex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Celldex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Celldex Therapeutics Inc

I send you an email if I find something interesting about Celldex Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Celldex Therapeutics Inc.

Receive notifications about Celldex Therapeutics Inc in your mailbox!